NCT01973491View on ClinicalTrials.gov

ATX-MS-1467 in Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Multiple Sclerosis
Interventions
DRUG

ATX-MS-1467

Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.

Trial Locations (1)

Unknown

Please contact the Merck KGaA Communication Center, Darmstadt

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01973491 - ATX-MS-1467 in Multiple Sclerosis | Biotech Hunter | Biotech Hunter